Last reviewed · How we verify
NCT05031065
Prognostic Indicators for Radiation-induced Breast Fibrosis
trial testing Breast Cancer Radiotherapy in Breast Cancer in 4 participants. Terminated before completion.
5 May 2025
Quick facts
| Lead sponsor | AHS Cancer Control Alberta |
|---|---|
| Status | Terminated |
| Study type | OBSERVATIONAL |
| Enrollment | 4 |
| Start date | 24 January 2024 |
| Primary completion | 5 May 2025 |
| Estimated completion | 5 May 2025 |
| Sites | 1 location across Canada |
Drugs / interventions tested
- Breast Cancer Radiotherapy
Conditions studied
- Breast Cancer — all drugs for Breast Cancer →
Sponsor
AHS Cancer Control Alberta — full company profile →
Who can join
40 and older, female only, with Breast Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
To study the inflammatory response during and after radiotherapy, especially by measuring the concentration of an enzyme called autotaxin and its product LPA in the blood plasma.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Single-cell transcriptome dynamics of the autotaxin-lysophosphatidic acid axis during muscle regeneration reveal proliferative effects in mesenchymal fibro-adipogenic progenitors.
Contreras O, Harvey RP. · · 2023 · cited 12× · PMID 36910157 · DOI 10.3389/fcell.2023.1017660
Verify or expand the search:
- PubMed search for NCT05031065
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Breast Cancer
Currently open trials in the same condition.
- NCT06148038 — CBD for Breast Cancer Primary Tumors · Phase 1 · recruiting
- NCT07405801 — A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R · Phase 2 · recruiting
- NCT07285993 — Detection and Outcomes in Metastatic Invasive Lobular Breast Cancer Through Novel F-18 FAP PET · Phase 2 · recruiting
- NCT07510698 — Same-Day Awake Mastectomy With Immediate Breast Reconstruction for Patients With Breast Cancer · NA · recruiting
- NCT06768931 — Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer · Phase 2 · recruiting
Other AHS Cancer Control Alberta trials
Trials by the same sponsor.
- NCT05128734 — Temozolomide Monotherapy or in Combination With Olaparib in Patients With Triple Negative Breast Cancer (TNBC) · Phase 2 · not yet recruiting
- NCT06860542 — Inhaled Budesonide for REcurrence Prevention and Adjuvant THerapy in Checkpoint Inhibitor Pneumonitis · Phase 2 · recruiting
- NCT05345847 — Steroid Sparing in Immune Related Hepatitis (irH) · NA · recruiting
- NCT05407987 — Ferric Derisomaltose and Outcomes in the Recovery of Gynecologic Oncology: ERAS (Enhanced Recovery After Surgery) · Phase 3 · recruiting
- NCT05421416 — Loratadine for the Prevention of G-CSF-related Bone Pain · Phase 2 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05031065 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AHS Cancer Control Alberta
- Last refreshed: 27 June 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05031065.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing